Holen Sie sich die Stockscreener-App
151.82
3.18%
4.65
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ILMN?
Forum
Prognose
Aktiensplit
Illumina Inc Aktie (ILMN) Neueste Nachrichten
Illumina and Powell Gilbert in love with Lisbon - JUVE Patent
Illumina stock hits 52-week high at 151.35 USD - Investing.com
North America Bioinformatics Market Size, Share, Trends, - openPR.com
Illumina Secures CMS Reimbursement for TruSight Oncology Test at $2,989.55 - Intellectia AI
Illumina Gets Medicare Boost for Cancer Test, Shares Climb - Benzinga
Customer Engagement Center - Illumina
Illumina secures CMS reimbursement for cancer genomic test at $2,989 - Investing.com
Illumina Gets Reimbursement For FDA-Approved TruSight Oncology Comprehensive Test, Stock Down - Nasdaq
Press Release - Illumina
Medicare to cover $2,989.55 Illumina genomic cancer test - Stock Titan
Stifel raises Illumina stock price target to $155 on growth outlook - Investing.com
GRAIL Inc.Illumina's Divested Holy Grail (NASDAQ:GRAL) - Seeking Alpha
Illumina Inc. (ILMN) Shares See Target Boost as Analysts See Potential 2026 Upside - Insider Monkey
The Technical Signals Behind (ILMN) That Institutions Follow - Stock Traders Daily
Illumina: What Is Next In This Sequence? (NASDAQ:ILMN) - Seeking Alpha
The Bull Case For Illumina (ILMN) Could Change Following Its Billion Cell Atlas Pharma Alliance - Yahoo Finance
Cathie Wood's Ark Unleashes Cryptic ARKmoji Teasers To Showcase Its 'Big Ideas' For 2026: Can You Take A Guess At The Hidden Meaning? - Benzinga
2MM: AI Roundup – Lilly and NVIDIA’s $1B AI lab, Illumina’s Billion Cell Atlas, AstraZeneca’s Modella deal, and Claude for Healthcare [Jan 19th, 2026] - 2 Minute Medicine
Is Now An Opportune Moment To Examine Illumina, Inc. (NASDAQ:ILMN)? - 富途资讯
Oncology Research Solutions - Illumina
Illumina Inc. Stock Underperforms Friday When Compared To Competitors - 富途资讯
Illumina, Inc.Common Stock (NQ: ILMN - FinancialContent
Illumina partners with pharma giants to map disease biology at unprecedented scale - Mugglehead Magazine
2026: A turning point for precision health - Illumina
Illumina reports preliminary Q4 revenue of $1.15B - MSN
Illumina's new connected multiomics platform set to boost its stock - MSN
Sumitomo Mitsui Trust Group Inc. Acquires 54,987 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina reports 5% revenue growth in Q4 2025, flat for full year - Investing.com Nigeria
Illumina launches billion cell atlas to boost AI-driven drug discovery - Investing.com Nigeria
Illumina Launches Billion Cell Atlas to Accelerate AI-Driven Drug Development - filmogaz.com
Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery - The Malaysian Reserve
Illumina CEO Sees Big Growth Opportunity in China - marketscreener.com
Illumina Announces Alliance Framework with AstraZeneca, Merck, and Eli Lilly and Company - marketscreener.com
JPM26: Illumina debuts Billion Cell Atlas to drive AI-driven drug discovery - Pharmaceutical Technology
Illumina Produces Midteens Earnings Growth in 2025, Distancing Itself From the Grail Debacle - Morningstar
Canada Next-Generation Sequencing (NGS) Market Analysis and Forecast, 2025-2035, Featuring Illumina, Oxford Nanopore Technologies, Pacific Bioscience of California, MGI Tech Co., QIAGEN and More - GlobeNewswire
Illumina (NASDAQ:ILMN) Updates Q4 2025 Earnings Guidance - MarketBeat
Illumina launches massive cell atlas to fast-track drug discovery - statnews.com
Press Release: Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025 - 富途牛牛
Illumina introduces Billion Cell Atlas, genome-wide genetic perturbation dataset - marketscreener.com
Illumina Billion Cell Atlas to accelerate AI, drug discovery - BioWorld MedTech
Illumina Introduces Illumina Billion Cell Atlas To Accelerate AI Drug Discovery - Nasdaq
Illumina unveils dataset to speed up AI-powered drug discovery - Reuters
Illumina introduces billion cell atlas to accelerate AI and drug discovery - marketscreener.com
Illumina Introduces Genetic Perturbation Dataset to Further AI Drug Discovery - marketscreener.com
Illumina reports 5% revenue growth in Q4 2025, flat for full year By Investing.com - Investing.com India
Illumina Preliminary Q4, Annual Results Beat Analysts' View - Nasdaq
Illumina launches billion cell atlas to boost AI-driven drug discovery By Investing.com - Investing.com South Africa
Illumina Reports Preliminary Fiscal Q4 Non-GAAP Earnings, Revenue - marketscreener.com
(ILMN) Illumina Expects 2025 Revenue About $4.34B, vs. FactSet Est of $4.28B - marketscreener.com
(ILMN) Illumina Expects Q4 Adjusted EPS Range $1.27 to $1.30, vs. FactSet Est of $1.21 - marketscreener.com
Inside Illumina's Billion Cell Atlas powering AI against disease - Stock Titan
Illumina Announces Preliminary Unaudited Financial Results for Q4 and Fiscal Year 2025 - TradingView — Track All Markets
Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025 - PR Newswire
Assessing Illumina (ILMN) Valuation After New Multiomics Platform And Chief Medical Officer Appointment - Yahoo Finance
DNA Methylation Sequencing Market Set to Revolutionize - openPR.com
2.80%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):